These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12670897

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.
    Cinatl J, Michaelis M, Driever PH, Cinatl J, Hrabeta J, Suhan T, Doerr HW, Vogel JU.
    Neoplasia; 2004; 6(6):725-35. PubMed ID: 15720798
    [Abstract] [Full Text] [Related]

  • 3. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T, Rabkin SD, Martuza RL.
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.
    Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y.
    Cancer Gene Ther; 2002 Nov; 9(11):935-45. PubMed ID: 12386832
    [Abstract] [Full Text] [Related]

  • 8. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
    Nakano K, Todo T, Zhao G, Yamaguchi K, Kuroki S, Cohen JB, Glorioso JC, Tanaka M.
    J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
    Cozzi PJ, Burke PB, Bhargav A, Heston WD, Huryk B, Scardino PT, Fong Y.
    Prostate; 2002 Oct 01; 53(2):95-100. PubMed ID: 12242723
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr 01; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
    Seitz G, Bonin M, Fuchs J, Poths S, Ruck P, Warmann SW, Armeanu-Ebinger S.
    Int J Oncol; 2010 Feb 01; 36(2):491-500. PubMed ID: 20043085
    [Abstract] [Full Text] [Related]

  • 16. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
    Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T, Yazaki T.
    J Gene Med; 2006 Nov 01; 8(11):1329-40. PubMed ID: 16955534
    [Abstract] [Full Text] [Related]

  • 17. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 18. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton PJ.
    Clin Cancer Res; 1999 Nov 15; 5(11):3617-31. PubMed ID: 10589779
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.
    Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A.
    Exp Neurol; 2001 May 15; 169(1):64-71. PubMed ID: 11312559
    [Abstract] [Full Text] [Related]

  • 20. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
    Liu TC, Wakimoto H, Martuza RL, Rabkin SD.
    Clin Cancer Res; 2007 Oct 01; 13(19):5897-902. PubMed ID: 17908985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.